-+ 0.00%
-+ 0.00%
-+ 0.00%

Spruce Biosciences Q2 FY26 net loss widens to $16.23 million; R&D expenses rise to $12.16 million

PUBT·08/12/2026 15:08:25
Listen to the news
Spruce Biosciences Q2 FY26 net loss widens to $16.23 million; R&D expenses rise to $12.16 million
  • Spruce Biosciences posted a Q2 net loss of USD 16.2 million, or USD 6.68 per share.
  • Cash and cash equivalents climbed to USD 96.3 million at June 30, from USD 48.9 million at Dec. 31.
  • R&D expense totaled USD 12.2 million; operating expenses reached USD 16.5 million, including USD 0.9 million in stock-based compensation.
  • TA-ERT BLA submission for MPS IIIB remains targeted for Q4 2026; accelerated approval path seeks CSF HS-NRE as surrogate endpoint.
  • TrAnsform confirmatory study, plus an expanded access program, are both expected to start in Q4 2026; advocacy groups invested USD 5.5 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260812480178) on August 12, 2026, and is solely responsible for the information contained therein.